Form 4: Esperion Therapeutics CFO Benjamin Halladay Sells Shares to Cover Tax Obligations

Esperion Therapeutics' Chief Financial Officer, Benjamin Halladay, sold 3,245 shares of common stock on December 17, 2024, to satisfy tax obligations related to vested restricted stock units.

Summary

• On December 17, 2024, Benjamin Halladay, the Chief Financial Officer of Esperion Therapeutics, Inc., sold 3,245 shares of common stock.
• The sale was executed at a price of $2.424 per share.
• This transaction was conducted to cover tax obligations arising from the vesting of restricted stock units.
• Following the transaction, Halladay directly owns 240,691 shares of Esperion Therapeutics stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The sale of shares to cover tax obligations is a neutral event and doesn't necessarily indicate positive or negative sentiment.

Industry Context

Sales of shares to cover tax obligations are a routine part of executive compensation, particularly when dealing with stock options or restricted stock units. It is a common practice and doesn't necessarily reflect a negative outlook on the company.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact given the reason for the sale.

Key Dates